Zosano Pharma Announces Additional Workforce Layoff The FDA had granted Zosano Pharma Corporation (NASDAQ: ZSAN) a twelve-month extension to April 20, 2023, to resubmit its M207 marketing application. Benzinga · May 2, 2022
FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ: IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma. Benzinga · May 2, 2022
U.S. FDA Rejects HUTCHMED's New Drug Application For Surufatinib In Neuroendocrine Tumors HUTCHMED (China) Limited (Nasdaq: HCM) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (NETs). Benzinga · May 2, 2022
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks during the week. Benzinga · May 2, 2022
Pressure builds for COVID vaccines approval for littlest kids Moderna's request for approval of its COVID -19 vaccine in children under six years amps up pressure on the Food and Drug Administration to act quickly to approve the shots. Axios · May 2, 2022
Editorial: The FDA rightly moves to extinguish menthol cigarettes The Food and Drug Administration has proposed banning menthol-flavored cigarettes, potentially beginning in 2024. It’s a tragedy that it is taking this long, but it’s never too late to save a life — or in this case, potentially hundreds of thousands of lives. Tribune News Service · May 2, 2022
Radiofrequency spinal cord stimulation shows improved longer-lasting pain relief: Study According to a new study, chronic pain spinal cord stimulation (SCS) uses an implanted device to supply a small amount of electricity directly to the spinal cord, altering or blocking nerve activity and minimizing the sensation of pain reaching the brain. Dynamite News · May 1, 2022
QNRX: FDA Clearance To Move QRX003 Clinical Testing Forward; Positive Implications By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Benzinga · Apr 30, 2022
U.S. FDA Approves AbbVie's RINVOQ® (upadacitinib) for Ankylosing Spondylitis (AS) The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) . Benzinga · Apr 29, 2022
FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA The FDA has set up June meeting dates to review COVID-19 vaccine submissions, noting that the dates are tentative as none of the submissions are complete. The agency reserved June 8, 21, and 22 for virtual meetings of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)… Benzinga · Apr 29, 2022
48 Stocks Moving In Friday's Mid-Day Session Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. Benzinga · Apr 29, 2022
FDA sets June meetings on COVID vaccines for youngest kids The Food and Drug Administration has set tentative dates in June to publicly review COVID-19 vaccines for the youngest American children The Independent UK · Apr 29, 2022
Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Friday. Benzinga · Apr 29, 2022
AOC Defends Due Process as Colleagues Greenlight Asset Seizure Bill Plus: Homeland Security's new Disinformation Governance Board, the FDA's menthol ban, and more... Reason · Apr 29, 2022
Benzinga · Apr 29, 2022 The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · Apr 29, 2022 74 Biggest Movers From Yesterday Gainers T Stamp Inc. (NASDAQ: IDAI) shares surged 123.8% to close at $4.70 on Thursday. Trust Stamp reported the launch of its Biometric Multi-Factor Authentication (Biometric MFATM) solution.
Benzinga · Apr 29, 2022 U.S. FDA Approves Bristol Myers Squibb's Camzyos™ (mavacamten) for the Treatment of Adults With obstructive HCM Bristol Myers Squibb (NYSE: BMY) announced the U.S.
Salon · Apr 28, 2022 White House: Paxlovid shortage is over As VP Harris takes Paxlovid after her COVID-19 diagnosis, the White House is making the drug easier to access
Benzinga · Apr 28, 2022 U.S. FDA removes Clinical Hold on Finch's investigational new drug (IND) application for CP101 The U.S. Food and Drug Administration (FDA) has removed the clinical hold on Finch Therapeutics Group (NASDAQ: FNCH) investigational new drug (IND) application for CP101 in the prevention of recurrent C. difficile infection (CDI).
Benzinga · Apr 28, 2022 Venus Concept Gets FDA 510(k) Clearance for Venus BlissMAX with expanded indication Venus Concept Inc. (NASDAQ: VERO) received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Venus BlissMAX device with an expanded indication for use in new areas of the body and an increase in RF energy output.
Salon · Apr 28, 2022 120,000 pounds of ground beef recalled Over 100,000 pounds of ground beef have been recalled over E. coli concerns
Reason · Apr 28, 2022 The FDA's Menthol Cigarette Ban Is a 'Racial Justice' Issue, but Not in the Way Its Supporters Mean The proposed rule, which targets the cigarettes that black smokers overwhelmingly prefer, will harm the community it is supposed to help.
Benzinga · Apr 28, 2022 Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6 Years Moderna Inc (NASDAQ: MRNA)
Tribune News Service · Apr 28, 2022 Herschel Walker spent years promoting health products with dubious claims ATLANTA — Senate candidate Herschel Walker has spent years promoting and developing health-conscious products with dubious benefits and a skepticism from the medical community, a review by The Atlanta Journal-Constitution has found.
Benzinga · Apr 28, 2022 FDA Gives Green Signal To Pfizer's Duchenne Gene Therapy Trial After the FDA lifted its hold on a late-stage study, Pfizer Inc (NYSE:PFE) said it would open the first U.S. trial sites for its experimental gene therapy for a muscle-wasting disorder. The FDA had put Pfizer's Investigational New Drug (IND) application for fordadistrogene movaparvovec on hold, and Pfizer has addressed the agency's requests related…